[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liu yong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100585003",false,"NCT06896708","Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome","Coronary Computed Tomography Study to Assess the Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome: A Nationwide, Multicentre, Randomized Controlled Trial","CAPITAL-PLAQUE","Inclusion Criteria:\n\n1\\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis.\n\n3\\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol\u002FL or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol\u002FL.\n\nExclusion Criteria:\n\n1. Left main coronary artery disease or severe three-vessel disease;\n2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;\n3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;\n4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol\u002FL in those taking statins and ≥4.9 mmol\u002FL in those not taking statins).\n5. Familial hypercholesterolemia;\n6. Known allergy\u002Fintolerance to lipid-lowering drugs used in the trial;\n7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;\n8. Pregnant or breastfeeding female patients.","ALL","18 Years","60 Years",{"count":20,"type":21},766,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \\\u003C1.0 mmol\u002FL and ≥50% reduction frome baseline) could delay progression of coronary atherosclerotic obstructive leisions compared with guideline recommended lipid-lowering therapy (goal for LDL-C \\\u003C1.8 mmol\u002FL and ≥50% reduction frome baseline) among participants between 18-60 years old with non-invasively managed chronic coronary syndrome (at least one lesion with a 50%-70% stenosis).",[27],"Chronic Coronary Syndrome","RECRUITING","2025-12-09",{"date":31,"type":32},"2025-12-17","ACTUAL",{"date":34,"type":32},"2025-08-12",{"date":36,"type":21},"2028-03-01",{"name":38,"class":39},"Liu yong","OTHER",7,""]